The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.
Smith S, Hoyt J, Whitebread N, Manna J, Peluso M, Faia K, Campbell V, Tremblay M, Nair S, Grogan M, Castro A, Campbell M, Ferguson J, Arsenault B, Nevejans J, Carter B, Lee J, Dunbar J, McGovern K, Read M, Adams J, Constan A, Loewen G, Sydor J, Palombella V, Soglia J.
Smith S, et al. Among authors: lee j.
Xenobiotica. 2013 Oct;43(10):875-85. doi: 10.3109/00498254.2013.780671. Epub 2013 Mar 25.
Xenobiotica. 2013.
PMID: 23527529